Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 20/20 | 0.79 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.79 |
| ▸ | HDAC10 | Q969S8 | 8/20 | 0.79 |
| ▸ | HDAC11 | Q96DB2 | 8/20 | 0.79 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.79 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.79 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.79 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.79 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.79 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 0.79 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.79 |
| ▸ | NCOR2 | Q9Y618 | 6/20 | 0.79 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.79 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.79 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.79 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.79 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.79 |
| ▸ | MTOR | P42345 | 1/20 | 0.79 |
| ▸ | PRKDC | P78527 | 1/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fimepinostat SCHEMBL29493089 | 0.88 | HDAC1 (1.00) | HDAC1HDAC2HDAC10HDAC11HDAC6 | |
| Fimepinostat SCHEMBL29353052 | 0.88 | HDAC1 (1.00) | HDAC1HDAC2HDAC10HDAC11HDAC6 | |
| Fimepinostat SCHEMBL1284705 | 0.88 | HDAC1 (1.00) | HDAC1HDAC2HDAC10HDAC11HDAC6 | |
| Fimepinostat SCHEMBL12813120 | 0.88 | HDAC1 (0.99) | HDAC1HDAC2HDAC10HDAC11HDAC6 | |
| Fimepinostat SCHEMBL12813051 | 0.88 | HDAC1 (0.99) | HDAC1HDAC2HDAC10HDAC11HDAC6 | |
| Fimepinostat SCHEMBL29666301 | 0.88 | HDAC1 (0.99) | HDAC1HDAC2HDAC10HDAC11HDAC6 | |
| Fimepinostat SCHEMBL29666166 | 0.88 | HDAC1 (0.99) | HDAC1HDAC2HDAC10HDAC11HDAC6 | |
| Fimepinostat SCHEMBL12813122 | 0.88 | HDAC1 (0.99) | HDAC1HDAC2HDAC10HDAC11HDAC6 | |
| Fimepinostat SCHEMBL12813054 | 0.88 | HDAC1 (0.99) | HDAC1HDAC2HDAC10HDAC11HDAC6 | |
| Fimepinostat SCHEMBL12813474 | 0.86 | HDAC1 (0.94) | HDAC1HDAC2HDAC10HDAC11HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3287459-B1 | PURINYL-N-HYDROXYL PYRIMIDINE FORMAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | GUIZHOU BAILING GROUP PHARMACEUTICAL CO LTD (CN) | 2020-09-02 | — | — | EP | disclosed |
| US-10227347-B2 | Purinyl-N-hydroxyl pyrimidine formamide derivative, preparation methods and uses thereof | GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD. (CN) | 2019-03-12 | — | — | US | disclosed |
| US-20180134709-A1 | PURINYL-N-HYDROXYL PYRIMIDINE FORMAMIDE DERIVATIVE, PREPARATION METHODS AND USES THEREOF | CHENGDU ZENITAR BIOMEDICAL TECHNOLOGY CO., LTD. (CN) | 2018-05-17 | — | — | US | disclosed |
| US-20180134709-A1 | PURINYL-N-HYDROXYL PYRIMIDINE FORMAMIDE DERIVATIVE, PREPARATION METHODS AND USES THEREOF | CHENGDU ZENITAR BIOMEDICAL TECHNOLOGY CO., LTD. (CN) | 2018-05-17 | — | — | US | disclosed |
| EP-3287459-A1 | PURINYL-N-HYDROXYL PYRIMIDINE FORMAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | Guizhou Bailing Enterprise Group Pharmaceutical Co., Ltd. (CN) | 2018-02-28 | — | — | EP | disclosed |
| WO-2016169417-A1 | PURINYL-N-HYDROXYL PYRIMIDINE FORMAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | 成都金瑞长青生物科技有限公司 | 2016-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134709-A1 | PURINYL-N-HYDROXYL PYRIMIDINE FORMAMIDE DERIVATIVE, PREPARATION METHODS AND USES THEREOF | HDAC5, HDAC2, HDAC8 | HDAC1 4/4885HDAC2 2/4885HDAC10 31/4885 |
| US-10227347-B2 | Purinyl-N-hydroxyl pyrimidine formamide derivative, preparation methods and uses thereof | HDAC5, HDAC2, HDAC8 | HDAC1 4/4885HDAC2 2/4885HDAC10 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.